News | August 16, 2023
Exor to buy 15% shareholding in Philips
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
The medical device sector is considered as one of the sunrise sectors in the country
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The inspection closed with zero observations and a classification of No Action Indicated
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
